Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact

Partner Post: Risperdal Anti-Psychotic Drug Settlement

by Brayton Purcell LLP | Nov 19, 2013 | Dangerous Medical Drugs

$2.2 Billion Risperdal Anti-Psychotic Drug Settlement 

Written by James P. Nevin  

Janssen, part of the well-known Johnson & Johnson company, pled guilty to misbranding its anti-psychotic medication Risperdal in a $2.2 billion dollar settlement. The company entered a guilty plea to one misdemeanor ending a complex legal case spanning almost a decade.

The settlement is the largest in U.S. history involving a single drug. It’s the result of four lawsuits filed in federal court in Philadelphia by whistle-blowers under the False Claims Act, which allows private citizens to sue on behalf of the government and share in the recoveries.

Janssen pled guilty to marketing the drug for uses not approved by the U.S. Food and Drug Administration. The company settled civil claims that it marketed Risperdal without approval for the elderly, children and the mentally disabled. Janssen allegedly sought to sell Risperdal to elderly patients for a wide range of off-label treatments including bipolar, dementia, and mood and anxiety disorders, the drug was only approved for the management of psychotic disorders. Through the company’s ElderCare sales force the drug was promoted to nursing homes even though it had never been tested on the elderly in clinical trials. The company has denied civil claims that it paid kickbacks to physicians and Omnicare Inc., the largest pharmacy for nursing homes.

As part of the settlement Johnson & Johnson signed a five-year corporate integrity agreement with the inspector general of the Department of Health and Human Services. Part of that agreement includes accountability, according to U.S. District Judge Timothy Savage, “this company is going to be under a magnifying glass for a period of time.”

 

Recent Posts

  • Who is Most at Risk of Mesothelioma?
  • Boiler Room Workers and Asbestos Exposure
  • Mitigating the financial impact of mesothelioma treatments
  • The EPA’s difficulty with data disclosure
  • Judge orders EPA to close loopholes on asbestos-related reporting

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us